ISSN: 1479-1641

Journal Home

Journal Guideline

Diabetes and Vascular Disease Research Q2 Unclaimed

SAGE Publications Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Diabetes and Vascular Disease Research is a journal indexed in SJR in Endocrinology, Diabetes and Metabolism and Internal Medicine with an H index of 60. It has an SJR impact factor of 0,775 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,775.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Cardiology and Cardiovascular Medicine (Q2) Endocrinology, Diabetes and Metabolism (Q2) Internal Medicine (Q2)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,775

SJR Impact factor

60

H Index

38

Total Docs (Last Year)

160

Total Docs (3 years)

1248

Total Refs

493

Total Cites (3 years)

153

Citable Docs (3 years)

2.29

Cites/Doc (2 years)

32.84

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Journal of Diabetes Q2
Molecular Genetics and Metabolism Q2
Journal of Endocrinological Investigation Q2
Journal of the Endocrine Society Q2
European Thyroid Journal Q2

Compare this journals

Aims and Scope

Best articles by citations

Diabetes alters cardiovascular responses to anaesthetic induction agents in STZ-diabetic rats

Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARa

High glucose-induced endothelial progenitor cell dysfunction

Do different definitions modify the gender-specific associations of metabolic syndrome with cardiovascular risk factors?

Effects of comprehensive intensive therapies on the change of intima-media thickness of carotid arteries in type 2 diabetic patients: A report of 4-year follow-up with a literature review

Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus

Plasma polyunsaturated fatty acid profile is associated with vascular endothelial function in patients with type 2 diabetes

Blood glucose and its prognostic implications in patients hospitalised with acute myocardial infarction

Co-existence of risk and protective haplotypes of Calpain 10 gene to type 2 diabetes in the eastern Indian population

Arterial elasticity in obese adolescents with clinical features of insulin resistance

Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity

Elastic properties and structure of the radial artery in patients with type 2 diabetes

SHOW MORE ARTICLES

Arterial hypertension defeated? Attacked from another angle

Endothelial dysfunction and cardiovascular disease - the lull before the storm

Cardiovascular disease markers in type 2 diabetes: the effects of a moderate home-based exercise training programme

Clinical implications of the metabolic syndrome

Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke

Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes

Variability of clopidogrel response in patients with type 2 diabetes mellitus

Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of Muller cells via Forkhead box protein O4

Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat

Survival of diabetes patients with major amputation is comparable to malignant disease

Sex-based differences in the association between duration of type 2 diabetes and heart rate variability

Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes